Gruppo Oncologico Italiano Di Ricerca Clinica

This study is testing whether adding an immunotherapy drug (dostarlimab) to standard chemotherapy (XELOX) after chemoradiation works better than chemotherapy alone for patients with a specific type of locally advanced rectal cancer. The goal is to better control the cancer and se…

This study is testing a personalized approach to treat advanced squamous non-small cell lung cancer. It will give patients a combination of an immunotherapy drug (cemiplimab) and one of two different chemotherapy regimens. The specific chemotherapy chosen for each patient is base…

This study is testing if a drug called avelumab can help control advanced bladder cancer for longer after patients finish a second round of chemotherapy. It will compare avelumab against standard supportive care in about 144 patients whose cancer has not gotten worse on their cur…

This study is for people with advanced clear-cell kidney cancer that has come back after they received a specific immunotherapy drug (pembrolizumab) as a preventative treatment after surgery. It aims to see if combining that same immunotherapy with a different drug (lenvatinib) c…

This study aims to better understand gastrointestinal cancers that occur in adults under 50. Researchers will observe about 150 newly diagnosed patients in Italy, collecting information about their tumors, treatments, and lifestyle habits like diet and smoking. The goal is to ide…

This study aims to understand why lung cancer returns in patients who had surgery and took the drug osimertinib afterward. Researchers will analyze tissue and blood samples from 100 patients whose cancer came back during or after treatment. The goal is to identify genetic changes…